Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

13.22 -6.31

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

13.87

Max

14.39

Chiffres clés
By Trading Economics
Revenu	-4.3M -18M
BPA	-0.19
Employés	37
EBITDA	-5.3M -17M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+105% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	57M 1.2B
Ouverture précédente	19.53
Clôture précédente	13.22

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 sept. 2026, 23:51 UTC

Australia's Consumer Confidence Index set for release amid mixed market sentiment and rising interest rate concerns.

7 sept. 2026, 23:51 UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, amid cautious optimism in the stock market despite global economic uncertainties.

7 sept. 2026, 23:51 UTC

UK Retail Sales Growth Slows to 0.5% YoY, Falling Short of Expectations Amid Consumer Caution

7 sept. 2026, 23:51 UTC

U.S. Initial Jobless Claims Expected at 205,000 Amid Strong Labor Market and Anticipated Fed Rate Hikes

7 sept. 2026, 23:51 UTC

China's Producer Prices Index Expected to Rise 3.7% Amid Mixed Economic Signals Ahead of September Release

7 sept. 2026, 23:41 UTC

Japan's Q2 2026 GDP Growth Rate Expected at 0.4% Amid Optimistic Economic Sentiment and Rising Nikkei Index

7 sept. 2026, 23:41 UTC

Japan's Q2 2026 GDP Growth Expected at +1.1% Amid Positive Economic Trends and Optimistic Market Sentiment

7 sept. 2026, 23:41 UTC

Japan's Current Account Expected at JPY 2,870 Billion Amid Positive Economic Sentiment and Speculation of Interest Rate Hikes.

7 sept. 2026, 23:31 UTC

ECB President Lagarde's Upcoming Speech Sparks Market Anticipation for Rate Hike Amid Rising Inflation and Geopolitical Tensions.

7 sept. 2026, 23:21 UTC

U.S. Core Inflation Rate Expected to Rise to 2.4% YoY Amid Strong Jobs Data, Heightening Speculation on Fed Interest Rate Hikes

7 sept. 2026, 23:21 UTC

Core Inflation Rate Release on September 11, 2026, Expected to Influence Fed's Interest Rate Decisions Amid Rising Geopolitical Tensions and Oil Prices.

7 sept. 2026, 23:21 UTC

Investors Brace for CPI Release Amid Rising Inflation Concerns and Fed Rate Hike Speculation on September 11, 2026.

7 sept. 2026, 23:21 UTC

U.S. Inflation Rate Expected to Rise 0.4% in August Amid Concerns of Federal Reserve Interest Rate Hikes Following Strong Job Growth

7 sept. 2026, 23:21 UTC

U.S. CPI Report on September 11, 2026 Expected to Show Inflation Rise Amid Market Caution and Fed Rate Hike Speculation

7 sept. 2026, 23:21 UTC

U.S. Inflation Rate Expected to Rise 3.4% YoY, Heightening Fed Rate Hike Speculations Amid Geopolitical Tensions and Oil Price Surge

7 sept. 2026, 23:11 UTC

U.S. Core Producer Prices Expected to Rise 0.3% in August Amid Geopolitical Tensions and Inflation Concerns

7 sept. 2026, 23:01 UTC

U.S. Producer Price Inflation (PPI) MoM for August set to release on September 10, with a forecasted rise of 0.4% amid inflation concerns and potential Fed interest rate hikes due to geopolitical tensions affecting oil prices.

7 sept. 2026, 23:01 UTC

NZD/JPY is lower today amid broader market volatility and geopolitical tensions following U.S. military actions against Iranian tankers. The pair remains near its one-month low.

7 sept. 2026, 23:01 UTC

Correlated Moves

AUD/JPY is trading lower, continuing a decline since Friday's close amid geopolitical tensions affecting investor sentiment and energy supply concerns.

7 sept. 2026, 23:01 UTC

Correlated Moves

GBP/JPY is declining amid heightened market volatility from geopolitical tensions and U.S. military actions, continuing lower since Friday's close.

7 sept. 2026, 23:01 UTC

Correlated Moves

CAD/JPY is declining, continuing a downward trend since Friday's close, influenced by geopolitical tensions and market volatility. The pair trades below its 20-day moving average.

7 sept. 2026, 23:01 UTC

Macro News

The USD/JPY currency pair is trading lower as the yen strengthens amid global economic uncertainties and tensions in the Middle East.

7 sept. 2026, 23:01 UTC

Correlated Moves

The EUR/JPY is lower today amid rising geopolitical tensions and a drop in USD/JPY. The exchange rate remains below its 20-day moving average.

7 sept. 2026, 23:01 UTC

Correlated Moves

CHF/JPY is trading lower as geopolitical tensions influence market sentiment, following a notable decline earlier in the session. The pair remains below its 20-day moving average.

7 sept. 2026, 22:51 UTC

Markets Anticipate ECB Deposit Facility Rate Hike Amid Rising Inflation and Geopolitical Tensions Ahead of September 10 Meeting.

7 sept. 2026, 22:21 UTC

India's Inflation Rate Release on September 14, 2026, Sparks Caution Amid Geopolitical Tensions and Rising Costs.

7 sept. 2026, 22:11 UTC

Mexico's Inflation Rate YoY for August 2026 set to release on September 9, with a forecast of 3.30% amid rising global oil prices and geopolitical tensions.

7 sept. 2026, 22:11 UTC

Mexico's Inflation Rate Expected to Rise 0.25% in August Amid Global Economic Pressures and U.S. Interest Rate Concerns.

7 sept. 2026, 22:01 UTC

MBA 30-Year Mortgage Rate Release on September 9, Amid Rising Rates and Anticipated Fed Hikes Influenced by Inflation Concerns.

7 sept. 2026, 21:51 UTC

Brazil's Central Bank to Announce Interest Rate Decision Amid Global Economic Uncertainty on September 8, 2026.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

105% hausse

Prévisions sur 12 Mois

Moyen 29.5 USD 105%

Haut 33 USD

Bas 27 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.